Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
about
Mimics and chameleons in motor neurone diseaseThe Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple SclerosisEvaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewNew and emerging immune-targeted drugs for the treatment of multiple sclerosisPrimary progressive multiple sclerosis: progress and challenges.Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.Progressive multiple sclerosis: from pathogenic mechanisms to treatment.Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.Regulatory T cells in multiple sclerosis and myasthenia gravis.Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.Novel somatic single nucleotide variants within the RNA binding protein hnRNP A1 in multiple sclerosis patients.Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells.Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Promoting remyelination: utilizing a viral model of demyelination to assess cell-based therapiesCharacteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.Histamine H(3) receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibilityA single-nucleotide polymorphism in serine-threonine kinase 11, the gene encoding liver kinase B1, is a risk factor for multiple sclerosisValidating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.The MRZ reaction in primary progressive multiple sclerosisUsing EAE to better understand principles of immune function and autoimmune pathologyDendritic cells and multiple sclerosis: disease, tolerance and therapy.Treatment trials in progressive MS--current challenges and future directions.Relapsing and progressive forms of multiple sclerosis: insights from pathology.Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.Intracellular Protein Shuttling: A Mechanism Relevant for Myelin Repair in Multiple Sclerosis?Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.Prothrombin and factor X are elevated in multiple sclerosis patients.Multiple Sclerosis: Immunopathology and Treatment Update.Multiple sclerosis and the blood-central nervous system barrier.Genetic burden of common variants in progressive and bout-onset multiple sclerosis.A Unique TGFB1-Driven Genomic Program Links Astrocytosis, Low-Grade Inflammation and Partial Demyelination in Spinal Cord Periplaques from Progressive Multiple Sclerosis Patients.The Optimization of Magnetic Resonance Imaging Pulse Sequences in Order to Better Detection of Multiple Sclerosis Plaques.Dynamic Changes in Brain Mesenchymal Perivascular Cells Associate with Multiple Sclerosis Disease Duration, Active Inflammation, and Demyelination.Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.
P2860
Q24619538-FE54CF05-9628-4540-8D57-B917E9274850Q26777944-D961128F-8659-4BE6-9F9C-08F3B33FB437Q26782408-31381461-0754-4435-96B2-8E314EE13EB5Q26997067-1E109197-9F79-4C23-8A3A-B82E0B48344AQ30590258-5AC42582-5031-44FA-8FD3-4C6DF7E3773CQ31027249-EF7449D1-84BC-4A0E-B0D4-BB0CFEFC6A7CQ31139925-2EA1CFDA-8EC4-47A1-98FA-2D2403DE1A02Q33768246-E690847B-3E38-40F7-AF14-0CABA5A16FD8Q33784969-31276721-D673-4AC4-86FC-B93C0A2ECFABQ33855341-0467E66E-6165-400A-B473-4C0E4D6C3EECQ34211413-96A2B641-AC51-4B4D-A065-595FD85C0194Q34250392-2BCBB135-B68C-4FEE-A24C-FDBA8BE83E9EQ34295012-2274BE4D-FD94-46D9-ABFA-8A5B2BE1FBFBQ34423587-08F22ECE-696C-4344-BF80-D4CE13B5CF94Q34468304-3BD2A525-6027-4143-A463-68991E6D55B7Q34512363-FD53739A-DC60-4B26-A4A6-1F9E8D8E2B43Q34700673-30A53E9C-9E53-4354-AC10-DAB43272085AQ34872216-3432D429-946E-4E82-AC8D-FCB8A7FDCBB0Q35126302-7A933D15-EBA2-4BFE-8B92-825C97ED50E9Q35126308-81587CDE-D1E3-4FE9-885F-B2F23179CCE3Q35722755-707C0906-AFDE-46BA-B03C-B93EA2AF73DFQ36293431-9DA6EBC2-2B0B-4FBE-B062-0E047F8D8662Q36613404-A5787AA2-CE84-4F43-B866-AB3CFD4DD4EBQ37628035-6D15F9BC-6FEB-4651-8F7C-0E9D456B2B4FQ37657501-87C2B58D-3D33-4B6B-91C1-F01FFBEF12C8Q38070093-7A070552-011D-46CA-8D13-B3D974C32C30Q38125123-3C43D51D-3B79-4F49-8F30-29AAB452AEB3Q38203770-8D4EBBDA-2B5E-459C-9EC2-2A06E131F406Q38299101-4DF5E7F0-530E-4785-91FC-9295B64D9F59Q38543597-69C702C5-9BCE-4EC9-ACB0-18BC4AD23E28Q38752155-195E2485-6A6C-425E-AE21-51E75918FDFCQ38806828-1DBCD3F1-A1C9-477F-BC5C-E9900155B088Q39420793-D6CB692B-83DB-4622-AE75-CE3ADEDEE6B7Q43136157-2812647B-B362-48AC-BA27-3B65705AE19FQ45381521-C33E216A-95E5-4AB6-914C-B536B801C585Q46989452-6862BB98-5CD3-4E1F-B8B1-4607BFDE092EQ47146763-CC6BE33C-1B9F-43F6-8138-E4AD29E04582Q48100073-90EC68E8-9403-40BE-9395-142FFAE2A60BQ48125672-9A3D287D-1002-431A-8999-8D9862F591F3Q48222881-F772F2AA-678A-43D7-88F6-FBAF60534CF4
P2860
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Primary progressive multiple s ...... um or separate disease entity?
@ast
Primary progressive multiple s ...... um or separate disease entity?
@en
Primary progressive multiple s ...... um or separate disease entity?
@nl
type
label
Primary progressive multiple s ...... um or separate disease entity?
@ast
Primary progressive multiple s ...... um or separate disease entity?
@en
Primary progressive multiple s ...... um or separate disease entity?
@nl
prefLabel
Primary progressive multiple s ...... um or separate disease entity?
@ast
Primary progressive multiple s ...... um or separate disease entity?
@en
Primary progressive multiple s ...... um or separate disease entity?
@nl
P2093
P2860
P1476
Primary progressive multiple s ...... um or separate disease entity?
@en
P2093
Douglas L Arnold
Jack Antel
Samson Antel
Tanja Kuhlmann
Zografos Caramanos
P2860
P2888
P304
P356
10.1007/S00401-012-0953-0
P577
2012-02-11T00:00:00Z